Argos Therapeutics, Inc. is developing fully personalized immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform that we believe can tackle a wide range of cancers and infectious diseases.
Argos Therapeutics Reports Second Quarter 2016 Financial Results and Recent Operational Highlights
Argos Therapeutics to Host Second Quarter 2016 Financial Results Conference Call on Wednesday, August 10, 2016
Argos Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock and Warrants